Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany

N. Ahmad Aziz, Victor M. Corman, Antje K. C. Echterhoff, Marcel A. Müller, Anja Richter, Antonio Schmandke, Marie Luisa Schmidt, Thomas H. Schmidt, Folgerdiena M. Vries, Christian Drosten and Monique M. B. Breteler ()
Additional contact information
N. Ahmad Aziz: German Center for Neurodegenerative Diseases (DZNE)
Victor M. Corman: Berlin Institute of Health
Antje K. C. Echterhoff: German Center for Neurodegenerative Diseases (DZNE)
Marcel A. Müller: Berlin Institute of Health
Anja Richter: Berlin Institute of Health
Antonio Schmandke: German Center for Neurodegenerative Diseases (DZNE)
Marie Luisa Schmidt: Berlin Institute of Health
Thomas H. Schmidt: German Center for Neurodegenerative Diseases (DZNE)
Folgerdiena M. Vries: German Center for Neurodegenerative Diseases (DZNE)
Christian Drosten: Berlin Institute of Health
Monique M. B. Breteler: German Center for Neurodegenerative Diseases (DZNE)

Nature Communications, 2021, vol. 12, issue 1, 1-10

Abstract: Abstract To estimate the seroprevalence and temporal course of SARS-CoV-2 neutralizing antibodies, we embedded a multi-tiered seroprevalence survey within an ongoing community-based cohort study in Bonn, Germany. We first assessed anti-SARS-CoV-2 immunoglobulin G levels with an immunoassay, followed by confirmatory testing of borderline and positive test results with a recombinant spike-based immunofluorescence assay and a plaque reduction neutralization test (PRNT). Those with a borderline or positive immunoassay result were retested after 4 to 5 months. At baseline, 4771 persons participated (88% response rate). Between April 24th and June 30th, 2020, seroprevalence was 0.97% (95% CI: 0.72−1.30) by immunoassay and 0.36% (95% CI: 0.21−0.61) when considering only those with two additional positive confirmatory tests. Importantly, about 20% of PRNT+ individuals lost their neutralizing antibodies within five months. Here, we show that neutralizing antibodies are detectable in only one third of those with a positive immunoassay result, and wane relatively quickly.

Date: 2021
References: Add references at CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://www.nature.com/articles/s41467-021-22351-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-22351-5

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-22351-5

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().